Abstract: A crystalline, completely soluble lithium bis(oxalato)horate (LiBOB), to a method for producing the same and to the use of the lithium bis(oxalato)borate.

Abstract: The invention relates to a process for preparing a stable 2-substituted benzofuran-3-yl borate ester corresponding to the formula: said process comprising contacting 3-bromo-2-substituted-benzofuran corresponding to the formula: with an C1-4 alkyllithium at a temperature less than ?60° C. to form 3-lithio-2-substititued-benzofuran, contacting the 3-lithio-2-substituted- benzofuran at a temperature less than ?60° C. with an borate ester corresponding to the formula: and recovering the resulting borate ester product, wherein, RW' is C1-4 alkyl; Rx is C1-10 hydrocarbyl or halohydrocarbyl; and RY independently each occurrence is C1-10 hydrocarbyl, halohydrocarbyl or trialkylsilylhydrocarbyl or 2 RY groups together are a divalent hydrocarbylene of up to 20 carbons.

Abstract: The present invention features compounds of formula (I): and salts thereof, pharmaceutical compositions comprising said compounds, and uses of such compounds in treating or preventing viral infections, such as HCV infections, and diseases associated with such infections.

Abstract: Provided herein are antimicrobial tricyclic boron compounds of the following formula I: or pharmaceutically acceptable salts, complexes, or tautomers thereof that are antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

Abstract: Compounds and methods of treating anti-inflammatory conditions are disclosed.

Abstract: The present invention provides compositions of matter useful as deposition agents for making structures, including thin film structures and hard coatings, on substrates and features of substrates. In an embodiment, for example, the present invention provides metal complexes having one or more diboranamide or diboranaphosphide ligands that are useful as chemical vapor deposition (CVD) and/or atomic layer deposition (ALD) precusors for making thin film structures and coatings. Metal complex CVD precursors are provided that possess volitilities sufficiently high so as to provide dense, smooth and homogenous thin films and coatings.

Abstract: Hafnium complexes of heterocyclic organic ligands having improved solubility in aliphatic hydrocarbon solvents and their use as components of olefin polymerization catalysts as well as novel syntheses of component parts thereof are disclosed.

Abstract: A magnesium battery, having an anode containing magnesium; a cathode stable to a voltage of at least 2.6 V relative to a magnesium reference; and an electrolyte containing an electrochemically active magnesium salt obtained by reaction of a Grignard reagent or Hauser base with a boron compound of formula BR3 is provided. The electrolyte is stable to 2.6 E.V. vs. Mg in the presence of stainless steel.

Abstract: The present invention relates to novel 2-oxo-2H-chromene-3-carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.

Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Abstract: A marker for determining the onset of periodontal disease and a marker far determining the progression stage of periodontal disease, each containing autoinducer-2.

Abstract: The present invention relates to novel derivatives that are suitable as precursors to compounds that are useful for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. The compounds deriving from these precursors are useful in methods of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease by positron emission tomography (PET) as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. Furthermore, the present invention also discloses the precursor compounds in crystalline form.

Abstract: Disclosed is a curable fluorine-containing polyether composition comprising (A) 100 parts by weight of a fluorine-containing polyether compound of the formula: wherein R1 is a hydrogen atom, a C1-C3 alkyl group, or a phenyl group, X is a bromine or iodine atom, l and m are integers of 10 or more, and l+m is 30 to 200; (B) 1 to 20 parts by weight of a fluorine-containing aromatic boronic acid ester compound of the formula: wherein R2 is a C2-C10 divalent aliphatic hydrocarbon group, and Y is a C1-C20 fluoroalkyl group; (C) 0.0001 to 1 parts by weight of a zero-valent or divalent organopalladium compound; (D) 0.5 to 10 parts by weight of a basic inorganic or organic compound; and (E) 0 to 5 parts by weight of an organophosphorus compound. The curable fluorine-containing polyether composition can produce a cured product that has improved compression set characteristics.

Abstract: The present invention relates in general to the field of organic chemistry and in particular to the preparation of ?-amino boronic acid derivatives.

Abstract: The invention provides catalysts and methods for preparing boronate esters. The methods can include the borylation of a secondary or primary C—H bond, for example, by contacting a reactant having a methylene or methyl and a diboron bis-ester in the presence of an effective catalyst. The contacting can be in the presence of an iridium complex, to effect borylation of the secondary or primary C—H bond, thereby providing the boronate ester. The boronate esters can be readily isolated and/or converted into other useful compounds and intermediates.

Abstract: The present invention provides compounds of Formula (I): along with compositions containing the same and methods of use thereof in treating oxidative stress.

Abstract: To provide a novel organoboron compound which is useful as a reactant of organic synthesis. To provide a method for manufacturing the organoboron compound. A novel organoboron compound represented by General Formula (G1) below is provided. Note that in General Formula (G1), R1 to R9 separately represent any one of hydrogen, an alkyl group having 1 to 6 carbon atoms, and an aryl group having 6 to 16 carbon atoms. R10 and R11 separately represent hydrogen or an alkyl group having 1 to 6 carbon atoms, and R10 and R11 may be bonded with each other to form a ring. Further, X represents an oxygen atom or a sulfur atom.

Abstract: [Problem] To provide an organoboron compound-containing reagent for organic synthesis reactions which undergoes no trimerization with dehydration, does not necessitate activation with a base, and is stable and highly active. [Means for Solving Problems] The reagent for organic synthesis reactions contains an organic triol borate salt represented by any of the general formulae (I) to (III) and general formula (XVI): (wherein R1 represents alkyl, alkenyl, etc.; R2 represents optionally substituted alkyl, alkenyl, alkynyl, etc. or represents hydrogen; m+ represents an alkaline metal ion, phosphonium ion, or given ammonium ion; M2+ represents an alkaline earth metal; X represents halogen or alkoxide; Y represents an alkali metal ion, etc.; A represents optionally substituted methylene; and n represents an integer).

Abstract: Provided is a novel anthracene compound represented by a general formula (G1). In the formula, Q1 represents an oxygen atom or a sulfur atom, R1 to R7 and R11 to R14 separately represent any one of a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, a substituted or unsubstituted phenyl group, and a substituted or unsubstituted biphenyl group. In addition, ?1 to ?3 separately represent a substituted or unsubstituted phenylene group. Ar1 represents a substituted or unsubstituted condensed aromatic hydrocarbon having 6 to 12 carbon atoms forming a ring. Ar2 represents any one of a substituted or unsubstituted aryl group having 6 to 12 carbon atoms forming a ring, a substituted or unsubstituted dibenzothiophen-2-yl group, and a substituted or unsubstituted dibenzofuran-2-yl group. Further, j and k are separately 0 or 1.

Abstract: The present invention provides a production process of a heteroaryl mono- or diboron compound comprising an aromatic heterocyclic compound and a boron compound in the form of bis(pinacolate)diboron or pinacolate diborane in the presence of a iridium-containing catalyst and a ligand such as a bipyridyl ligand. The reaction is conducted in a single step under mild conditions and allows for changing the charged ratios of the raw materials.

Abstract: Compounds according to Formula I are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, D, W, X, Y, and Z are defined in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use in treating or preventing a disease or a condition associated with arginase activity.

Abstract: The present invention relates to a method for manufacturing a boronic acid ester compound, characterized by reacting an aryl halide compound and a diboron ester compound in the presence of a nitrogen-containing organic base, a nickel catalyst, a phosphine compound and a solvent. According to the manufacturing method of the present invention, even if a nickel catalyst is used as the catalyst, a desired boronic acid ester compound can be obtained in a sufficiently high yield. Furthermore, even if aryl chloride or aryl bromide having relatively low price and low reactivity, was used as the aryl halide compound, a desired boronic acid ester compound can be obtained in a sufficiently high yield.

Abstract: A compound of formula (I) is described; wherein the substituents are as defined in the text and wherein the compound is intended for use in the production of a vascular damaging effect in a warm-blooded animal.

Abstract: Boron chelate complexes of the general formula are described, where X is either —C(R1R2)— or —C(R1R2)—C(?O)—, in which R1, R2 independently of one another denote H, alkyl (with 1 to 5 C atoms), aryl, silyl or a polymer, and one of the alkyl radicals R1 or R2 may be bonded to a further chelatoborate radical, or X denotes 1,2-aryl with up to two substituents S in the positions 3 to 6 in which S1, S2 independently of one another denote alkyl (with 1 to 5 C atoms), fluorine or a polymer, as well as M+ denotes Li+, Na+, K+, Rb+, Cs+ or [(R3R4R5R6)N]+ or H+, where R3, R4, R5, R6 independently of one another denote H or alkyl with preferably 1 to 4 C atoms.

Abstract: Methods and compound useful for detecting a source of hydrogen peroxide are disclosed wherein a signalling compound of the formula: is reacted with peroxide. Sig is a non-polymeric organic group, B is a boron atom, and each R is independently selected from hydrogen, alkyl and aryl groups and can be joined together as a straight or branched alkylene chain forming a ring or as an aromatic ring. A detectable product compound of the formula Sig-OH or Sig-O?is produced and detected by measuring color, absorbance, fluorescence, chemiluminescence, or bioluminescence. The signalling compound itself does not possess the detectable property or does so only to a very weak degree. The methods can be used as a detectable signal in assays for peroxide or peroxide-producing enzymes and in assays employing enzyme-labeled specific binding pairs.

Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.

Abstract: Novel organic compounds comprising azaborine are provided. In particular, the compounds comprise a dibenzo-1,4,-azaborine core having a phenyl substituent on the boron atom, and aryl or heteroaryl substituents at positions 2 and 6 of the phenyl substituent. These compounds may be advantageously used in organic light-emitting devices to provide improved efficiency and lifetime.

Abstract: A fluorine-containing boronic acid ester represented by the general formula: (R1 is a linear or branched divalent aliphatic hydrocarbon group having 2 to 10 carbon atoms, R2 is a hydrogen atom, an alkyl group having 1 to 3 carbon atoms or phenyl group, n is an integer of 1 to 3, and m is an integer of 0 to 4) having an improved solubility in organic solvents is produced by reacting a fluorine-containing 3,5-dihalogenoanilide derivative represented by the general formula: (R2 is a hydrogen atom, an alkyl group having 1 to 3 carbon atoms or phenyl group, X is a halogen atom, n is an integer of 1 to 3, and m is an integer of 0 to 4) with a dialkoxyborane represented by the general formula: (R1 is a linear or branched divalent aliphatic hydrocarbon group having 2 to 10 carbon atoms).

Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Abstract: The present invention relates to a process for preparing nebivolol and, more particularly, to a process for preparing d-nebivolol and its enantiomer l-nebivolol or acid addition salts thereof starting from commercially available or easily obtainable 2,2-dimethyl-1,3 dioxolane-4-carbaldehyde and a vinyl Grignard reagent.

Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Abstract: The present invention relates to dyes of the general formula CAT+ Y? (I), where Y? is an anion selected from the group of the cyanoborates, fluoroalkylphosphates, fluoroalkylborates or imidates and CAT+ is a cation selected from the group of the azine, xanthene, polymethine, styryl, azo, tetrazolium, pyrylium, benzopyrylium, thiopyrylium, benzothiopyrylium, thiazine, oxazine, triarylmethane, diarylmethane, methine, acridine, quinoline, isoquinoline or quaternary azafluorenone dyes, for colouring plastics and plastic fibres, for the preparation of flexographic printing inks, as ball-point pen pastes, as stamp ink, for colouring leather and paper, for use in data acquisition systems, reprography, in ink microfilters, in photogalvanics, laser technology and the photo industry.

Abstract: Disclosed is a method for producing a BSH derivative, which comprises a step of addition-reacting BSH with an ?,?-unsaturated nitrile compound in the presence of a base. Various BSH derivatives obtained by the method are also disclosed.

Abstract: This invention provides, among other things, polymorphs of the hydrochloride salt of (S)-3-aminomethyl-7-(3-hydroxy-propoxy)-3H-benzo[c][1,2]oxaborol-1-ol.

Abstract: The present invention provides a novel class of pro-fluorescent probes for reactive oxygen species (ROS). One exemplary probe is mitochondria peroxy yellow 1 (MitoPY1), a new type of flurophore for imaging mitochondrial H2O2 in living cells with ROS and spatial specificity. The invention also provides methods of using pro-fluorescent probes to detect analytes. One exemplary method comprises using a pro-fluorescent probe of the invention to detect an explosive.

Abstract: A fluorine-containing boronic acid ester compound (R1: a linear or branched divalent aliphatic hydrocarbon group having 2 to 10 carbon atom, m: 1 to 5, and n: 3 to 7) having a low melting point is produced by reacting a 3,5-dihalogeno fluorine-containing phenol derivative with a dialkoxyborane The fluorine-containing boronic acid ester compound is highly soluble in organic solvents and has a low melting point. The fluorine-containing boronic acid ester compound can suitably be used as a starting material for the production of conjugated polymer materials or as a curing agent for elastomeric polymer materials.

Abstract: The present invention provides a compound represented by the following general formula (I): or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing such a compound, and the like. The compound or a pharmaceutically acceptable salt thereof, the pharmaceutical composition containing such a compound, or the like is useful as a medicine or the like for therapy of benign prostatic hyperplasia, cancer, osteoporosis, psoriasis, secondary hyperparathyroidism, chronic glomerulonephritis, lupus nephritis and/or diabetic nephropathy and the like.

Abstract: The present invention relates to a method for forming a silica-based particle or composite consisting of a silica-based material, an active, with or without a surface modification, and the related composition. The silica-based particle is illustrated by the formula (SiO2)x(OH)yRzSt, whereby R is an active or actives such as an organic or inorganic molecule that includes markers, amines, thiols, epoxies, organosilicones, organosilanes, and water soluble agents and, optionally, a surface modifier, S, which may be either organic, polymeric, or inorganic. Examples of a surface modifying material are inorganic salts of aluminum and boron or organic materials such as organosilanes or low molecular weight polymers. As such, the particle can be used in a variety of applications including any of a variety of high temperature, at acidic, neutral, or basic pH, or pressure environments.

Abstract: The present invention relates to a method for forming a silica-based particle or composite consisting of a silica-based material, an active, with or without a surface modification, and the related composition. The silica-based particle is illustrated by the formula (SiO2)x(OH)yRzSt, whereby R is an active or actives such as an organic or inorganic molecule that includes markers, amines, thiols, epoxies, organosilicones, organosilanes, and water soluble agents and, optionally, a surface modifier, S, which may be either organic, polymeric, or inorganic. Examples of a surface modifying material are inorganic salts of aluminum and boron or organic materials such as organosilanes or low molecular weight polymers. As such, the particle can be used in a variety of applications including any of a variety of high temperature, at acidic, neutral, or basic pH, or pressure environments.

Abstract: The present invention provides a novel class of fluorogenic probes for reactive oxygen species. Exemplary probes of the invention utilize a boronate deprotection mechanism to provide high selectivity and optical dynamic range for detecting H2O2 in aqueous solution over similar reactive oxygen species (ROS) including superoxide, nitric oxide, tert-butyl hydroperoxide, and hydroxyl radical; Peroxyresorufin-1 (PR1), Peroxyfluor-1 (PF1), and Peroxyxanthone-1 (PX1) are first-generation probes that respond to H2O2 by an increase in red, green, and blue fluorescence, respectively. The boronate dyes are cell-permeable and can detect micromolar changes in H2O2 concentrations in living cells, including hippocampal neurons, using confocal and two-photon microscopy. The unique combination of ROS selectivity, membrane permeability, and a range of available excitation/emission colors establishes the potential value of PR1, PF1, PX1, and related probes for interrogating the physiology and pathology of cellular H2O2.

Abstract: An intermediate compound for total synthesis of ecteinascidins comprising, a compound represented by general formula 2 having thioether group at C4 site, and the substituent R2 of N12 site is trichloroethoxycarbonyl (Troc) to which various substituents can be introduced by mild condition, further having 10 members ring structure which can be converted to a ring of other numbered members.

Abstract: This invention provides, among other things, novel oxaboroles which are monosubstituted at the 3-, 6-, or 7-position, or disubstituted at the 3-/6- or 3-/7- positions, which are useful for treating bacterial infections, pharmaceutical compositions containing such oxaboroles, as well as combinations of these oxaboroles with at least one additional therapeutically effective agent.

Abstract: This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections.

Abstract: A stabilized borane-tetrahydrofuran complex is disclosed. Also disclosed are processes for the preparation of the borane-tetrahydrofuran complex and methods of storing and transporting the prepared complex. The borane-tetrahydrofuran complexes exhibit enhanced shelf life and increased self-accelerated decomposition temperatures.

Abstract: A stabilized deuteroborane-tetrahydrofuran complex is disclosed. Also disclosed are processes for the preparation of the deuteroborane-tetrahydrofuran complex and methods of storing and transporting the prepared complex. The deuteroborane-tetrahydrofuran complexes exhibit enhanced shelf life and increased self-accelerated decomposition temperatures.

Abstract: The present invention provides a light emitting device material which enables a light emitting device having high efficiency and excellent chromatic purity and durability using a light emitting device material containing a pyrene compound represented by formula (1), wherein any one of R1 to R10 is a group represented by formula (2), or 1 to 4 substituents is/are group(s) represented by formula (3), and a light emitting device using the same.

Abstract: The present invention provides compositions of matter useful as deposition agents for making structures, including thin film structures and hard coatings, on substrates and features of substrates. In an embodiment, for example, the present invention provides metal complexes having one or more diboranamide or diboranaphosphide ligands that are useful as chemical vapor deposition (CVD) and/or atomic layer deposition (ALD) precusors for making thin film structures and coatings. Metal complex CVD precursors are provided that possess volitilities sufficiently high so as to provide dense, smooth and homogenous thin films and coatings.

Abstract: The invention includes coupling compounds, rubber compositions, and tires. The coupling compounds can, for example, be used to couple to silica filler. Rubber compositions can comprise the coupling compound and polymers. Polymers can be homopolymers, copolymers and terpolymers, and can include repeat units provided from conjugated diene monomers. Tires and various parts of tires can be made from those rubber compositions.

Abstract: The present disclosure encompasses compounds and compositions that are useful as specific AI-2 antagonists for the control of bacterial quorum sensing. Although the AI-2 antagonists according to the present disclosure may not have bactericidal effect, their ability to attenuate virulence, drug resistance, and/or biofilm formation have therapeutic benefits. In addition, the AI-2 antagonists of the present disclosure can also be used as tools to probe bacterial AI-2 functions. The present disclosure also encompasses methods for inhibiting or attenuating microbial virulence, biofilm formation, and drug resistance. The methods are suitable for preventing bacteria from accruing and forming extensive biofilms that may be a health or hygiene hazard or a physical issue, such as in the blockage of water or fuel lines.

Abstract: Boron chelate complexes of the general formula are described, where X is either —C(R1R2)— or —C(R1R2)—C(?O)—, in which R1, R2 independently of one another denote H, alkyl (with 1 to 5 C atoms), aryl, silyl or a polymer, and one of the alkyl radicals R1 or R2 may be bonded to a further chelatoborate radical, or X denotes 1,2-aryl with up to two substituents S in the positions 3 to 6 in which S1, S2 independently of one another denote alkyl (with 1 to 5 C atoms), fluorine or a polymer, as well as M+ denotes Li+, Na+, K+, Rb+, Cs+ or [(R3R4R5R6)N]+ or H+, where R3, R4, R5, R6 independently of one another denote H or alkyl with preferably 1 to 4 C atoms.